Clinical Trials Directory

Trials / Conditions / Recurrent Bladder Carcinoma

Recurrent Bladder Carcinoma

16 registered clinical trials studyying Recurrent Bladder Carcinoma — 2 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With
NCT06733363
Roswell Park Cancer InstitutePhase 2
WithdrawnsEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer
NCT03552796
University of Southern CaliforniaPhase 1
CompletedTrigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig
NCT03229278
Rutgers, The State University of New JerseyPhase 1
Active Not RecruitingSapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mut
NCT03047213
National Cancer Institute (NCI)Phase 2
CompletedPembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
NCT02808143
Northwestern UniversityPhase 1
TerminatedsEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
NCT02767921
University of Southern CaliforniaPhase 1
CompletedNanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
NCT02646319
Mayo ClinicEARLY_Phase 1
CompletedPembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
NCT02437370
University of California, DavisPhase 1
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph
NCT02465060
National Cancer Institute (NCI)Phase 2
TerminatedErlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
NCT02169284
National Cancer Institute (NCI)Phase 2
CompletedSirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
NCT01938573
University of WashingtonPhase 1 / Phase 2
CompletedRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun
NCT01638533
National Cancer Institute (NCI)Phase 1
CompletedVaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
NCT01522820
Roswell Park Cancer InstitutePhase 1
RecruitingCollecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate o
NCT01050504
University of Washington—
CompletedPhase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
NCT00118040
National Cancer Institute (NCI)Phase 2
TerminatedNeoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystec
NCT00072137
National Cancer Institute (NCI)Phase 1